Skip to main content
Premium Trial:

Request an Annual Quote

Battling Pancreatic Cancer

Premium

National Foundation for Cancer Research scientist Michael Sporn is working on a new class of anti-cancer drugs for the prevention of pancreatic cancer. Sporn, who is known at NFCR as "the father of chemoprevention," and his team at Dartmouth Medical School, have designed and synthesized triterpenoids — synthetic compounds that target and inhibit biological processes like inflammation, which play a role in the formation of the disease. "Recently, the researchers demonstrated that the triterpenoids, CCDO-Me and CCDO-EA, inhibited important inflammatory molecules in pancreatic cell lines and slowed the development of the harmful effects of pancreatic cancer in laboratory models that closely resemble the disease in humans," the Foundation says. Now the researchers are working on figuring out the mechanism by which triterpenoids work, and whether they can be used with standard pancreatic cancer therapies to make them more effective.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.